Hematopoietic allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with hematological malignancies. However, due to disparities in major and minor histocompatibility antigens between donor and recipient, severe inflammatory complications can occur, among which chronic graft-versus-host disease (cGVHD) can be life-threatening. A classical therapeutic approach to the prevention and treatment of cGVHD has been broad immunosuppression, but more recently adjuvant immunotherapies have been tested. This review summarizes and discusses immunomodulatory approaches with T cells, including chimeric antigen receptor (CAR) and regulatory T cells, with natural killer (NK) cells and innate lymphoid cells (ILCs), and finally with mesenchymal stromal cells (MSC) and extracellular vesicles thereof. Clinical studies and pre-clinical research results are presented likewise.
CITATION STYLE
Doglio, M., Crossland, R. E., Alho, A. C., Penack, O., Dickinson, A. M., Stary, G., … Inngjerdingen, M. (2022, November 17). Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2022.1045168
Mendeley helps you to discover research relevant for your work.